The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Breast Cancer Research And Treatment
Bardia, Aditya A; Mayer, Ingrid I; Winer, Eric E; Linden, Hannah M HM; Ma, Cynthia X CX; Parker, Barbara A BA; Bellet, Meritxell M; Arteaga, Carlos L CL; Cheeti, Sravanthi S; Gates, Mary M; Chang, Ching-Wei CW; Fredrickson, Jill J; Spoerke, Jill M JM; Moore, Heather M HM; Giltnane, Jennifer J; Friedman, Lori S LS; Chow Maneval, Edna E; Chan, Iris I; Jhaveri, Komal K
Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study - a multicentre prospective observational cohort study.
Bmj Open
Janssen, Liselore M LM; Suelmann, Britt B M BBM; Elias, Sjoerd G SG; Janse, Markus H A MHA; van Diest, Paul J PJ; van der Wall, Elsken E; Gilhuijs, Kenneth G A KGA
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Therapeutic Advances In Medical Oncology
Lloyd, Maxwell R MR; Wander, Seth A SA; Hamilton, Erika E; Razavi, Pedram P; Bardia, Aditya A
Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability.
Cells
Jeffreys, Sarah A SA; Powter, Branka B; Balakrishnar, Bavanthi B; Mok, Kelly K; Soon, Patsy P; Franken, André A; Neubauer, Hans H; de Souza, Paul P; Becker, Therese M TM
Phase and context shape the function of composite oncogenic mutations.
Nature
Gorelick, Alexander N AN; Sánchez-Rivera, Francisco J FJ; Cai, Yanyan Y; Bielski, Craig M CM; Biederstedt, Evan E; Jonsson, Philip P; Richards, Allison L AL; Vasan, Neil N; Penson, Alexander V AV; Friedman, Noah D ND; Ho, Yu-Jui YJ; Baslan, Timour T; Bandlamudi, Chaitanya C; Scaltriti, Maurizio M; Schultz, Nikolaus N; Lowe, Scott W SW; Reznik, Ed E; Taylor, Barry S BS
Targeted mutation detection in breast cancer using MammaSeq™.
Breast Cancer Research : Bcr
Smith, Nicholas G NG; Gyanchandani, Rekha R; Shah, Osama S OS; Gurda, Grzegorz T GT; Lucas, Peter C PC; Hartmaier, Ryan J RJ; Brufsky, Adam M AM; Puhalla, Shannon S; Bahreini, Amir A; Kota, Karthik K; Wald, Abigail I AI; Nikiforov, Yuri E YE; Nikiforova, Marina N MN; Oesterreich, Steffi S; Lee, Adrian V AV
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Cancer Discovery
Toy, Weiyi W; Weir, Hazel H; Razavi, Pedram P; Lawson, Mandy M; Goeppert, Anne U AU; Mazzola, Anne Marie AM; Smith, Aaron A; Wilson, Joanne J; Morrow, Christopher C; Wong, Wai Lin WL; De Stanchina, Elisa E; Carlson, Kathryn E KE; Martin, Teresa S TS; Uddin, Sharmeen S; Li, Zhiqiang Z; Fanning, Sean S; Katzenellenbogen, John A JA; Greene, Geoffrey G; Baselga, José J; Chandarlapaty, Sarat S
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Nature Communications
Spoerke, Jill M JM; Gendreau, Steven S; Walter, Kimberly K; Qiu, Jiaheng J; Wilson, Timothy R TR; Savage, Heidi H; Aimi, Junko J; Derynck, Mika K MK; Chen, Meng M; Chan, Iris T IT; Amler, Lukas C LC; Hampton, Garret M GM; Johnston, Stephen S; Krop, Ian I; Schmid, Peter P; Lackner, Mark R MR
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Nature Genetics
Toy, Weiyi W; Shen, Yang Y; Won, Helen H; Green, Bradley B; Sakr, Rita A RA; Will, Marie M; Li, Zhiqiang Z; Gala, Kinisha K; Fanning, Sean S; King, Tari A TA; Hudis, Clifford C; Chen, David D; Taran, Tetiana T; Hortobagyi, Gabriel G; Greene, Geoffrey G; Berger, Michael M; Baselga, José J; Chandarlapaty, Sarat S